Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
Retrieved on:
Thursday, May 13, 2021
To date, no safety signals of concern have emerged and none of the participants have dropped out from the study.
Key Points:
- To date, no safety signals of concern have emerged and none of the participants have dropped out from the study.
- Goldberg brings more than 20 years of industry experience, working across clinical development, drug discovery and medical genetics.
- Prior to this, Dr. Goldberg served in various roles at Xenon Pharmaceuticals including Senior VP, Clinical Development.
- Michael R. Hayden, CEO and Founder of Prilenia , commented: \xe2\x80\x9cWe are delighted that Dr. Y Paul Goldberg joins the Prilenia team.